Back to search

Article

Development of a clinically implementable population pharmacokinetic– pharmacodynamic model and interactive application for therapeutic drug monitoring of amrubicin

2026-04-06

Abstract excerpt

<title>Abstract</title> <p>Background Amrubicin is an important chemotherapeutic agent for small cell lung cancer; however, severe neutropenia is a major dose-limiting toxicity. Exposure to its active metabolite, amrubicinol, correlates with neutropenia severity, suggesting its potential role in therapeutic drug monitoring (TDM). This study aimed to develop a clinically implementable pharmacokinetics (PK)–pharma...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5f9ee253-9eb7-583f-bae6-8707d335c9bf
DOI
10.21203/rs.3.rs-9191032/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Development of a clinically implementable population pharmacokinetic– pharmacodynamic model and interactive application for therapeutic drug monitoring of amrubicinDOI 10.21203/rs.3.rs-9191032/v1
Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity
Individualized Meropenem Dosing in CRRT Patients: Development and Validation of a Machine Learning-Based Decision Support ToolSemantic proximity
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.Semantic proximity
Quantitative systems pharmacology modeling of avadomide-induced neutropenia enables virtual clinical dose and schedule finding studiesSemantic proximity
Population Pharmacokinetics and Factors Influencing Trough Concentration of Voriconazole in Children with Hematological MalignanciesSemantic proximity
Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity
Comprehensive statistical analysis of the pharmacokinetics, safety and clinical benefit rate of MitoTam in a single-center phase I/Ib trial in patients with metastatic solid tumorsSemantic proximity
Automated modeling of population pharmacokinetic models using nlmixr2auto: a clinical trial and real-world data studySemantic proximity
An Interpretable PK-Informed Hybrid Model for Voriconazole Exposure Prediction: Roles of CYP2C19 Genotype and Inflammation.Semantic proximity
Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approachSemantic proximity
Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibitionSemantic proximity
Select a neighboring publication to make it the new centre.